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Abstract: Most patients with Parkinson’s disease (PD) experience sleep-related problems, such 
as difficulty in initiating and maintaining sleep, excessive daytime sleepiness, sleep fragmenta-
tion, reductions in non-rapid eye movement (NREM) or rapid eye movement (REM) sleep, and 
REM sleep behavior disorder. Although motor symptoms of PD are treated with dopaminergic 
drugs, the nonmotor symptoms pose a big problem, and they often precede the onset of the 
disease. Treating the nonmotor symptoms, such as sleep and associated behavioral disorders, 
is beneficial, for it not only relieves the symptoms but also helps to slow the progression of the 
disease. Treating PD patients with melatonin has been shown to be beneficial in treating sleep 
and behavior problems. The finding of reduced expression of the MT
1
 and MT
2
 melatonin recep-
tors in amygdalae and substantia nigra of PD patients supports the involvement of melatonergic 
system in the etiology of PD. Hence, the use of melatonin or its analogs may even be beneficial 
not only for improving sleep quality but also for enhancing neuroprotection in PD.
Keywords: REM sleep-behavior disorder, insomnia, melatonin receptors, circadian 
dysregulation
Introduction
Parkinson’s disease (PD) affects millions of people all over the world, and its key 
symptoms include tremor, rigidity, postural instability, and bradykinesia.  Nonmotor 
symptoms of PD include rapid eye movement (REM) sleep behavior disorder (RBD), 
depression, and mania, which may often precede the onset of disease, and of these, 
RBD even serves as a preclinical marker of PD.1 The prevalence of sleep disturbances 
in PD is very high.2–6 Although the etiology of sleep disorders in PD is not clearly 
known, dysregulation of the circadian components of the sleep-regulating system 
is said to be involved in this disease.7 A number of studies involving PD patients 
have shown that both sleep induction and sleep maintenance are affected. The onset 
and timing of REM sleep is very much impaired in PD patients.8 Treatment of sleep 
disorders associated with PD with appropriate drugs will not only help in promoting 
sleep and reducing the severity of sleep problems but also will help in slowing the 
progression of PD itself.9 As melatonin, the major neurohormone secreted by the 
pineal gland, has significant circadian rhythm regulatory function through its MT
1
 
and MT
2
 receptors in the central circadian clock, namely the suprachiasmatic nucleus 
(SCN), interest has been focused on the use of melatonin in treating sleep disorders 
associated with PD. This review discusses the sleep disturbances associated with PD 
and also the treatment options, mainly melatonin and its agonists in treating PD.
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Circadian dysregulation in PD
There is much evidence for the possible involvement of the 
retinohypothalamic system in the etiology of PD, since cir-
cadian rhythm disturbances are common in this disease.10,11 
The SCN seems to be intact in PD patients, and the possible 
cause for circadian rhythm sleep disorders in PD is that a 
decrease in melatonergic receptors occurs in the amygdala 
and the substantia nigra of PD patients,12 and that this reduc-
tion coexists with PD-associated sleep disturbances.
Parkinsonian symptoms themselves undergo circadian 
fluctuations.7 Patients with PD often experience worsening 
of symptoms in the afternoon and evening. They experience 
time-dependent responsiveness to dopaminergic  stimulation.10 
Fertl et al reported that levodopa-treated PD patients but not 
de novo PD patients showed a phase advance of the mela-
tonin circadian rhythm.13,14 The phase advance in PD patients 
treated with l-dopa/decarboxylase inhibitor is possibly due 
to a central nervous dopaminergic effect elicited by l-dopa 
administration and not inherent to Parkinson’s disease per se.14 
Bordet et al confirmed those results, and showed no changes 
in locomotor activity, cortisol, or temperature rhythms in de 
novo PD patients.15 In this study, a decrease in amplitude of 
circulating melatonin rhythm was also observed. In a recent 
study, PD patients with excessive daytime sleepiness had a 
significantly lower amplitude of the melatonin rhythm and 
24-hour melatonin area under the curve (P0.001) compared 
to patients without excessive daytime sleepiness (Epworth 
Sleepiness Scale score $10).11 In this study, circadian dys-
function may have underlain excessive sleepiness in PD. 
However, the nature of this association needs to be explored 
further in longitudinal studies.
Recently, many studies of molecular clock mechanisms 
regulating circadian physiology and behavior in mammals 
have been undertaken in the central circadian pacemaker, 
the SCN, and various peripheral tissues and cells.16 Several 
circadian genes, known as key “clock genes”, have been 
identified. Of these, PER1 and BMAL1 are regarded as the 
best markers of the molecular clock. Disruptions of BMAL1 
and PER1 in mice have been shown to cause altered circadian 
behavior and dysregulation of circadian patterns in gene 
expression.17–19 The circadian clock genes PER1 and BMAL1 
have been located in leukocytes of healthy humans and hence, 
study of these genes in patients with PD has been recently 
undertaken.20,21 PER1 and BMAL1 expression in leukocytes 
of patients with PD and normal controls were investigated 
between 9 pm and 9 am. It was noticed that the expression 
of BMAL1 but not PER1 was greatly reduced during this 
dark phase, suggesting that a peripheral molecular clock is 
altered in PD patients. Moreover, BMAL1 expression in PD 
patients correlated with the Unified PD Rating Scale score at 
6 am and 9 am and with the Pittsburgh Sleep Quality Index 
Score at 6 am.20,21
Sleep disorders in PD
Sleep disorders constitute one of the major nonmotor features 
of PD, and even serve as a preclinical marker of the disease. 
Between 42% and 98% of patients with PD experience sleep-
related symptoms.22,23 Sleep disturbances in PD encompass 
difficulty initiating sleep, frequent nighttime awakening and 
sleep fragmentation, nocturia, restless leg syndrome/periodic 
limb movements, sleep breathing disorders, drug-induced 
symptoms, RBD, sleep attacks, reduced sleep efficiency, and 
excessive daytime sleepiness.24
These sleep disorders are classified as primary sleep dis-
orders that are intrinsic to PD and those that are secondary 
to medication, etc.25 Among the nonmotor symptoms of PD, 
sleep disturbances and particularly RBD are very important, 
and even predict the diagnosis of PD as ascertained by motor 
symptoms.26,27
RBD in PD
RBD in PD is poorly understood, and may occur as a 
prodromal feature predating motor symptoms by several 
years. Its prevalence is about 60% in PD patients, and it has 
been suggested to be predictive of dementia in longitudinal 
studies.26,27 However, mild cases of RBD may be missed 
by clinical interview but revealed by polysomnography. In 
the International Classification of Sleep Disorders, second 
edition, RBD is subcategorized under parasomnias usually 
associated with REM sleep, and polysomnography findings 
are required to establish the diagnosis.28 RBD is character-
ized by a loss of atonia, with prominent motor activity and 
dreaming.22 Numerous cases of RBD have been found in 
clinically diagnosed PD.29–31
The patient states of being, ie, wakefulness, non-REM 
sleep, and REM sleep, are not necessarily mutually exclu-
sive, and components of these states may appear in various 
combinations, with intriguing clinical consequences. RBD 
is an intrusion of wakefulness into REM sleep, due to the 
absence of REM sleep atonia.24,32 The loss of REM sleep 
atonia and/or increased locomotor drive is suggested as the 
likely mechanism for the clinical expression of human RBD.31 
The loss of REM sleep atonia manifests as a dream disorder 
similar to REM motor disorder, and there is a tendency for 
the dream content to involve an aggressive, attacking, or 
chasing theme. Nightmare behaviors like screaming, kicking, 
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punching, and injuring the bed partner are quite common.29–31 
Nocturnal disturbances and sleep arousals, as measured by 
actigraphy, are specific to the RBD seen in PD patients. In a 
study conducted on the hypothalamuses of eleven PD patients 
and five control subjects, a loss of hypothalamic hypocretin 
and melanin-concentrating hormone-producing neurons has 
been found in PD.33 However, a recent study undertaken with 
regard to these issues indicated that changes in orexin/hypo-
cretin do not necessarily underpin RBD sleep  disturbances.34 It 
is suggested that probing into the components of the circadian 
system that mediates the onset and timing of REM sleep, 
including the pattern and timing of melatonin secretion, com-
bined with clinical pathological studies may prove to be vital 
for defining the neuroanatomical correlates of RBD in PD.7
Sleep fragmentation  
and difficulties in initiation  
and maintenance of sleep
Sleep fragmentation is the most common sleep-related mani-
festation of PD; its prevalence is nearly 40%,35 and it occurs 
concomitantly with PD motor disorders.36 Overall difficulties 
in falling asleep or maintaining restorative sleep are com-
mon in PD. Disorders of sleep initiation and maintenance 
are characterized either by reduction in stages 3 and 4 of 
non-REM sleep or by decrease of REM sleep.37 Restless leg 
syndrome is most prevalent in PD,38 and an obstructive and 
central type of apnea is seen in 20% of PD patients.4,5,39 In a 
study conducted on PD patients using a self-rated sleep log 
for assessing sleep quality, it was found that daily well-being 
was more severely affected in moderately/severely affected 
patients than less severely affected patients.40 The most com-
monly used dopaminergic drugs may affect sleep and degrade 
quality of life in PD patients.41 A primary approach for treating 
sleep disorders in PD is to use sleep hygiene, but the results 
have not been encouraging, and hence hypnotic drugs have 
been recommended. However, these drugs need to be used 
with caution because of their potential side effects.42 Using 
short-acting hypnotic drugs, such as zolpidem,43 which have 
less impact on muscle relaxation, is recommended to prevent 
falls associated with sleep aids, especially in elderly subjects. 
The relative lack of safe pharmacological tools for tackling PD 
sleep problems has necessitated turning to safer drugs like the 
naturally occurring melatonin, its slow-release preparations, 
or its agonists like ramelteon or agomelatine.44
Melatonin and its receptors
Melatonin is mainly synthesized in the pineal gland, and its 
synthesis is regulated by the SCN, which also acts as the 
central circadian pacemaker. The production and release 
of melatonin is very high during the dark of night – around 
200 pg/mL – and is low in the daytime – 10 pg/mL.45  Synthesis 
of melatonin occurs in other regions of the body, such as the 
retina, gastrointestinal tract, skin, ovaries, lymphocytes, and 
thymus.46 Melatonin exerts its physiological actions by acting 
through G-protein-coupled receptors, namely MT
1
 and MT
2
 
melatonin receptors, expressed either singularly or combined 
together in various cells and tissues of the body.47 Melatonin 
receptors have been identified in different regions of the brain, 
such as the SCN,48 hippocampus,49 and central dopaminergic 
pathways, including the substantia nigra, caudate, putamen, 
ventral tegmental area, and nucleus accumbens.50 The signal-
transduction pathways for MT
1
 melatonin receptors are 
coupled to different G proteins that cause adenylyl cyclase 
inhibition and phospholipase C activation.51–53 MT
2
 receptors 
are coupled to a number of signal-transduction pathways that 
cause phosphoinositide production, inhibition of adenylyl 
cyclase, and guanylcyclase.54 A third melatonin-binding site 
known as MT
3
 has been identified as quinine reductase.55 
Melatonin also exerts some of its actions by binding with 
calmodulin, reticulin, and also with orphan nuclear receptors 
of retinoic acid superfamily retinoid Z receptor-β, retinoic 
acid receptor (RAR)-related orphan receptor (ROR)-α and 
RORα-2.56–58 Studies on the expression of MT
1
 and MT
2
 
receptors in human amygdalae and substantia nigra have 
shown that they are very much decreased when compared 
to normal subjects.12
Melatonin as a therapeutic  
agent in the treatment of PD
Experimental animal studies have shown that melatonin, an 
effective antioxidant, offers neuroprotection and has potential 
for treating cognitive disorders in PD.59,60 Also, melatonin 
has been used for treating sleep problems, insomnia, and 
daytime sleepiness. In a study involving 40 patients with PD 
(29 males and eleven females, mean age 61.7±8.4 years, range 
43–76 years) for a treatment period of 2 weeks, melatonin 
was administered in doses ranging from 5 mg to 50 mg/day.53 
Melatonin was administered (5 or 50 mg) 30 minutes before 
bedtime to avoid any possible circadian phase shift, as such 
shifts can occur if melatonin is administered at any other time. 
All subjects were taking stable doses of antiparkinsonian 
medications during the course of the study. Treatment with 
50 mg of melatonin significantly increased nighttime sleep 
(P0.05) compared to placebo, as revealed by actigraphy. 
Subjective reports of overall sleep disturbance improved 
significantly on 5 mg of melatonin when compared to 50 mg 
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or placebo. It was found that high doses of melatonin were 
well tolerated in this study.61
In a double-blind placebo-controlled trial of RBD that 
utilized melatonin at a dosage of 3 mg/day, four patients 
had complete resolution of the disturbance, two patients had 
marked improvement, one patient showed a little improve-
ment, and one patient remained unchanged. The data suggest 
that melatonin might be a second useful agent besides clon-
azepam in the treatment of RBD.62 In a later study, a higher 
dosage of melatonin, 15 mg at bedtime, was reported to be 
effective.63 In a recent study conducted on 38 patients with 
PD (15 males and 23 females, mean age 67.3±4.8 years) and 
complaints of sleep disorders, either melatonin 3 mg along 
with the usual dopaminergic drug or clonazepam 2 mg along 
with a dopaminergic agonist was administered at night for 
6 weeks. It was noted in this study that both melatonin and 
clonazepam reduced sleep disorders in their respective groups. 
With clonazepam, patients showed daytime sleepiness, which 
was not seen with melatonin treatment. The PD Sleep Scale 
was employed in this study. Neuropsychological testing, as 
assessed by the Mini-Mental State Examination, showed that 
the melatonin group had better scores. From this study, it was 
concluded that melatonin has high treatment efficacy for the 
treatment of sleep disorders associated with PD.64
In another study involving 30 patients with early and late 
stages of PD, a decrease by 21% (P0.05) in chronic fatigue 
syndrome on the Parkinson Fatigue Scale, improvement of 
sleep on the PD Sleep Scale (PDSS), a decrease in the anxiety 
state on Spielberger’s scale, and an improvement in quality 
of life on the 39-item Parkinson’s Disease  Questionnaire 
(P0.05) were found after melatonin treatment. From this 
study, it was concluded that melatonin together with opti-
mized antiparkinsonian treatment can treat chronic fatigue 
syndrome and improve the sleep and quality of life of PD 
patients.65
The therapeutic use of melatonin in treating sleep disor-
ders associated with PD, including RBD, was supported in 
a recent review paper.66 Using salivary dim-light melatonin 
onset and actigraphy, research has shown that PD patients 
treated with dopaminergic therapy (medicated PD) demon-
strated less circadian disturbance than unmedicated PD group 
and controls.67 In another study, it was found that serum 
melatonin levels correlated with PD severity according to 
the Hoehn and Yahr scale.68
With the finding of reduced expression of the MT
1
 and 
MT
2
 melatonin receptors in patients with PD, there is a possi-
bility that the melatonergic system is involved in the  abnormal 
sleep mechanisms seen in PD and in the pathophysiology of 
PD. Therefore, therapeutic strategies should target the use 
of melatonin and its agonists, such as ramelteon, to treat 
subjective sleep disturbances, sleep quantity, and daytime 
sleepiness.69 The use of melatonin as an adjunct therapy to 
Slows the progression
of PD
Treats REM
sleep behavior
disorder (RBD)
Treats sleep disorders
in PD
Melatonin
Promotes sleep Regulates sleep–wake
rhythm
MT1 and MT2 melatonin
receptors
Arrests free radical
accumulation
Effective antioxidant
Figure 1 Melatonin’s neuroprotective and sleep regulating role in PD.
Abbreviations: PD, Parkinson’s disease; ReM, rapid eye movement.
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either halt disease progression or provide symptomatic relief 
in PD has been gaining more importance in recent times. The 
neuroprotective actions of melatonin in Parkinson’s disease 
are presented in Figure 1.
Bright-light treatment,  
melatonin, and PD
Exposure to light of 1,000–1,500 lux for 1–1.5 hours, 1 hour 
prior to bedtime at 10 pm for 2–5 weeks, in 12 patients has 
improved the bradykinesia and rigidity observed in PD.70 A 
reduction in agitation and psychiatric side effects were also 
reported in this study. Activation of the circadian system 
by antagonizing melatonin secretion with bright light has 
been suggested as the possible mechanism for treating the 
symptoms of PD.10 Bright light has been employed in treating 
depressive symptoms. However, suppression of melatonin 
secretion is not the likely mechanism by which artificial light 
exerts its therapeutic effect.71 Two possible mechanisms have 
been proposed for the possible therapeutic effects of bright 
light. First, bright light could reset the phase of abnormal 
circadian rhythms seen in depressed patients.71 Second, eve-
ning bright-light exposure, though it produces momentary 
melatonin suppression, actually causes a rebound increase 
of melatonin secretion in the late-night period.72 Bright-light 
exposure ultimately facilitates melatonin secretion rather 
than suppressing it, and this is said to be responsible for the 
therapeutic efficacy of bright light in affective disorders. 
Therefore, in case of PD, bright light might also improve the 
symptoms of PD, certainly not by antagonizing melatonin 
secretion but instead inducing the rebound effect of enhanc-
ing melatonin secretion. Light therapy has been shown to 
offer the advantages of neuroprotection, which is not provided 
by dopamine-replacement therapy, and hence it is advocated 
for treating the disease itself.73
Conclusion and implications  
for future therapy
Animal models of PD indicate that free radical generation in 
the nigrostriatal system is involved in the pathogenesis of PD. 
Since nonmotor symptoms of PD, such as sleep disorders, 
particularly REM sleep disorder, occur in the majority of PD 
patients and can present long before PD motor symptom mani-
festations, treating the sleep disorders of PD may be essential 
both for preventing and delaying the progression of this 
disease. Current evidence points to melatonin and melatonin 
receptors in PD pathophysiology. Therapeutic strategies for 
the control of PD should consider the therapeutic application 
of melatonin or its receptor agonists, such as ramelteon and the 
melatonergic antidepressant agomelatine. To date, melatonin 
alone has been employed for treating sleep disorders and RBD, 
and has been found to be effective in treating nonmotor symp-
toms of the disease. In future, large numbers of clinical trials 
are required, as melatonin not only sets right the sleep disorders 
associated with the disease but treats the disease itself, since 
it has sufficient antioxidant activity. By its dual therapeutic 
actions acting as a chronohypnotic (a drug that can promote 
sleep and set right a disturbed sleep–wake rhythm) and as an 
effective antioxidant, melatonin can arrest the progression of 
PD when administered in the early stages of disease.
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